Literature DB >> 29110506

Mouse population-based evaluation of urinary protein and miRNA biomarker performance associated with cisplatin renal injury.

Alison H Harrill1,2,3, Haixia Lin1, Julia Tobacyk2, John C Seely4.   

Abstract

Discovery and qualification of novel biomarkers with improved specificity and sensitivity for detection of xenobiotic-induced injuries is an area of active research across multiple sectors. However, the majority of efforts in this arena have used genetically limited rodent stocks that lack variability in xenobiotic responses inherent to genetically heterogeneous human populations. In this study, genetically diverse Diversity Outbred (DO) mice were used as a surrogate for human clinical populations to investigate performance of urinary kidney biomarkers against classical preclinical kidney injury biomarkers (blood urea nitrogen [BUN] and serum creatinine). In this study, cisplatin was used as a paradigm kidney toxicant, with female adult DO mice exposed to a single injection (5 mg/kg) of cisplatin or vehicle and necropsied 72 h post-exposure and 18 h following overnight urine collection. Interindividual variability in kidney toxicity was observed, with DO mice experiencing either no tubule cell necrosis or minimal-mild necrosis. A panel of urinary protein biomarkers and profiled miRNAs were assessed by receiver-operating characteristic curves as to their ability to distinguish non-responder versus responder animals, as defined by histopathological evidence of renal tubule cell necrosis. A surprising outcome of these studies was that BUN was elevated alongside of urinary miRNA and protein biomarkers in animals with grade 2 proximal tubular cell necrosis; but not elevated with grade 1 necrosis. These studies demonstrate a novel approach for using a rodent population to better assess sensitivity of candidate biomarkers, especially for proposed clinical applications. Impact statement Recent studies have indicated that several urinary proteins and miRNA species may be suitable as biomarkers for acute kidney injury. A major focus on biomarker qualification is demonstrating improved specificity and sensitivity over gold standard tests. In this study, a mouse population model, Diversity Outbred mice, was used to demonstrate that neither the urinary protein markers nor the miRNA species assayed in urine could reliably detect low severity kidney injury better than blood urea nitrogen. This study has implications for use of these biomarkers in the clinic, where interindividual heterogeneity is present within patient populations and for which the underlying tissue pathology may not be known.

Entities:  

Keywords:  Biomarkers; Diversity Outbred; cisplatin; kidney; kidney injury molecule-1; miRNA

Mesh:

Substances:

Year:  2017        PMID: 29110506      PMCID: PMC5813868          DOI: 10.1177/1535370217740854

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  29 in total

1.  Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery.

Authors:  Jaya Mishra; Catherine Dent; Ridwan Tarabishi; Mark M Mitsnefes; Qing Ma; Caitlin Kelly; Stacey M Ruff; Kamyar Zahedi; Mingyuan Shao; Judy Bean; Kiyoshi Mori; Jonathan Barasch; Prasad Devarajan
Journal:  Lancet       Date:  2005 Apr 2-8       Impact factor: 79.321

2.  Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury.

Authors:  T Ichimura; J V Bonventre; V Bailly; H Wei; C A Hession; R L Cate; M Sanicola
Journal:  J Biol Chem       Date:  1998-02-13       Impact factor: 5.157

3.  Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR).

Authors:  Evan M Kroh; Rachael K Parkin; Patrick S Mitchell; Muneesh Tewari
Journal:  Methods       Date:  2010-02-08       Impact factor: 3.608

4.  Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase.

Authors:  Ryan M Franke; Ashley M Kosloske; Cynthia S Lancaster; Kelly K Filipski; Chaoxin Hu; Oliver Zolk; Ron H Mathijssen; Alex Sparreboom
Journal:  Clin Cancer Res       Date:  2010-07-02       Impact factor: 12.531

5.  Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2.

Authors:  Giuliano Ciarimboli; Thomas Ludwig; Detlef Lang; Hermann Pavenstädt; Hermann Koepsell; Hans-Jürgen Piechota; Jörg Haier; Ulrich Jaehde; Jochen Zisowsky; Eberhard Schlatter
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

6.  Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury.

Authors:  Won K Han; Veronique Bailly; Rekha Abichandani; Ravi Thadhani; Joseph V Bonventre
Journal:  Kidney Int       Date:  2002-07       Impact factor: 10.612

7.  Identification of urinary microRNA biomarkers for detection of gentamicin-induced acute kidney injury in rats.

Authors:  Xiaobing Zhou; Zhe Qu; Cong Zhu; Zhi Lin; Yan Huo; Xue Wang; Jufeng Wang; Bo Li
Journal:  Regul Toxicol Pharmacol       Date:  2016-04-10       Impact factor: 3.271

8.  Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice.

Authors:  Xia Wen; Brian Buckley; Elizabeth McCandlish; Michael J Goedken; Samira Syed; Ryan Pelis; José E Manautou; Lauren M Aleksunes
Journal:  Am J Pathol       Date:  2014-03-15       Impact factor: 4.307

9.  Quantitative trait locus mapping methods for diversity outbred mice.

Authors:  Daniel M Gatti; Karen L Svenson; Andrey Shabalin; Long-Yang Wu; William Valdar; Petr Simecek; Neal Goodwin; Riyan Cheng; Daniel Pomp; Abraham Palmer; Elissa J Chesler; Karl W Broman; Gary A Churchill
Journal:  G3 (Bethesda)       Date:  2014-09-18       Impact factor: 3.154

10.  High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus.

Authors:  Elkin Navarro-Quiroz; Lisandro Pacheco-Lugo; Hernan Lorenzi; Yirys Díaz-Olmos; Lisneth Almendrales; Edwin Rico; Roberto Navarro; Pierine España-Puccini; Antonio Iglesias; Eduardo Egea; Gustavo Aroca
Journal:  PLoS One       Date:  2016-11-11       Impact factor: 3.240

View more
  7 in total

Review 1.  Model systems and organisms for addressing inter- and intra-species variability in risk assessment.

Authors:  Ivan Rusyn; Weihsueh A Chiu; Fred A Wright
Journal:  Regul Toxicol Pharmacol       Date:  2022-05-28       Impact factor: 3.598

2.  Selenium Status in Diet Affects Nephrotoxicity Induced by Cisplatin in Mice.

Authors:  Shuang Liu; Xing Wen; Qihan Huang; Minghui Zhu; Jun Lu
Journal:  Antioxidants (Basel)       Date:  2022-06-10

Review 3.  Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury.

Authors:  Sara J Holditch; Carolyn N Brown; Andrew M Lombardi; Khoa N Nguyen; Charles L Edelstein
Journal:  Int J Mol Sci       Date:  2019-06-20       Impact factor: 5.923

4.  MicroRNAs in toxic acute kidney injury: Systematic scoping review of the current status.

Authors:  Fathima Shihana; Melissa L Barron; Fahim Mohamed; Devanshi Seth; Nicholas A Buckley
Journal:  Pharmacol Res Perspect       Date:  2021-04

Review 5.  Dysregulated MicroRNAs as Biomarkers or Therapeutic Targets in Cisplatin-Induced Nephrotoxicity: A Systematic Review.

Authors:  Nadine de Godoy Torso; João Kleber Novais Pereira; Marília Berlofa Visacri; Pedro Eduardo Nascimento Silva Vasconcelos; Pía Loren; Kathleen Saavedra; Nicolás Saavedra; Luis A Salazar; Patricia Moriel
Journal:  Int J Mol Sci       Date:  2021-11-25       Impact factor: 5.923

Review 6.  MicroRNAs Involved in Intrinsic Apoptotic Pathway during Cisplatin-Induced Nephrotoxicity: Potential Use of Natural Products against DDP-Induced Apoptosis.

Authors:  Pía Loren; Yuliannis Lugones; Nicolás Saavedra; Kathleen Saavedra; Isis Páez; Nelia Rodriguez; Patricia Moriel; Luis A Salazar
Journal:  Biomolecules       Date:  2022-08-31

Review 7.  Epigenetic Mechanisms Involved in Cisplatin-Induced Nephrotoxicity: An Update.

Authors:  Pía Loren; Nicolás Saavedra; Kathleen Saavedra; Tomás Zambrano; Patricia Moriel; Luis A Salazar
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.